Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?

 Following years of hushed excitement and mounting anticipation in biotech circles, gene and cell therapies finally made the jump in 2017 from the safety of guarded clinical trial experimentation to broad availability to patients and their caregivers in the USA.  The USA’s FDA (Food and Drug Administration) approvals of the…

CAR-T Combos: Potentially the Next Big Thing in Solid Tumors, Yet Pricing ‘Sticker Shock’ is not the Only Hurdle to be Overcome

After years of anticipation, CAR-Ts (chimeric antigen receptor–T-cells) finally made the transition from being promising future therapies, to breakthrough marketed products in 2017. Novartis’s KYMRIAH™ got the FDA nod in late August for pediatric B-ALL (B-cell acute lymphoblastic leukemia), followed by Kite’s YESCARTA™ in October for NHL (Non-Hodgkin lymphoma) (Figure 1)….

WHO Stands to Benefit the most from the Biosimilars Prequalification Programme?

Most companies prioritise launching innovative therapies in high-income countries due to their greater ability and willingness to pay.  This greater funding opportunity allows for earlier adoption of innovative, high-value products, which help to fulfil commercial expectations and realise returns on their research and development investment.  As a result, these high-income…

STRIMVELIS™ – The Proof Is In The Messaging

In an unprecedented move, GBR’s (United Kingdom) NICE (National Institute for Health and Care Excellence) recently recommended NHS (National Health Services) funding of $GSK’s gene therapy STRIMVELIS™ for an ultra-orphan immunodeficiency disorder ADA-SCID1 – also dubbed the “Bubble Baby Syndrome” – at EUR 594,000 (ex-VAT2 price, about USD 700,000). Importantly,…

Page 1 of 7123...Last »